NCT00830388 is a Phase 4 clinical trial of Ketoconazole 2% Foam in Tinea Versicolor, sponsored by Boni Elewski, MD.

Who is sponsoring NCT00830388?

NCT00830388 is sponsored by Boni Elewski, MD.

What drugs are being tested in NCT00830388?

Interventions in NCT00830388: Ketoconazole 2% Foam.

What condition does NCT00830388 study?

NCT00830388 studies Tinea Versicolor.

Is NCT00830388 still recruiting?

NCT00830388 is currently completed. Last updated 21 August 2012.

Are results published for NCT00830388?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2012-08-21 · How we verify

NCT00830388

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Ketoconazole Foam 2% for the Treatment of Versicolor

Completed Phase 4 Results posted Last updated 21 August 2012

What this trial tests

Phase 4 trial testing Ketoconazole 2% Foam in Tinea Versicolor in 11 participants. Completed in 1 September 2010.

Timeline

1 November 2008

Primary endpoint
1 August 2010

1 September 2010

Quick facts

Lead sponsor	Boni Elewski, MD
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	11
Start date	1 November 2008
Primary completion	1 August 2010
Estimated completion	1 September 2010
Sites	1 location across United States

Drugs / interventions tested

Ketoconazole 2% Foam — full drug profile →

Conditions studied

Tinea Versicolor — all drugs for Tinea Versicolor →

Sponsor

Boni Elewski, MD

Who can join

19 and older, any sex, with Tinea Versicolor. Healthy volunteers can join.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

The Effect of Ketoconazole 2% Foam for the Treatment of Tinea Versicolor
Time frame: 4 weeks
Eleven participants were tested for the microscopic presence of yeast. At four weeks, all participants were re-tested and deemed positive if yeast continued to be present microscopically.

Sponsor's own description

Ten adult patients age 19 and older with a clinical diagnosis of tinea versicolor, as well as a positive Potassium Hydroxide (KOH) using calcofluor. Ketoconazole 2% foam will be used to determine its effectiveness, safety and satisfaction when used to treat tinea versicolor.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Tinea Versicolor

Currently open trials in the same condition.

NCT05730244 — A Study of the Clinical Efficacy and Safety of 20% Cassia Alata Extract Against Tinea Versicolor · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00830388 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Boni Elewski, MD
Last refreshed: 21 August 2012

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00830388.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing